Treatment type
Treatments and trials using Oral Medicine, with the same country and access zoom as New Developments.
All New Developments
Kerendia (finerenone) — once-daily oral pill to lower urine protein in adults with kidney disease and type 1 diabetes
FDA supplemental approval announced 17 September 2026 for a new use of Kerendia (finerenone) tablets — a once-daily oral non-steroidal…
This is for adults with type 1 diabetes who already have chronic kidney disease with protein in the urine and…
Joenja (leniolisib) — first labelled oral treatment for children 4–11 with APDS who weigh at least 27 kg
FDA supplemental approval on 11 September 2026 for Joenja (leniolisib) tablets — expanding the labelled APDS door to adult and pediatric patients 4…
This is for caregivers of children 4–11 years with genetically confirmed APDS who weigh at least 27…
Etcamah (camizestrant) — oral ER antagonist with CDK4/6 for ESR1m HR+/HER2− advanced breast cancer
FDA accelerated approval on 4 September 2026 for Etcamah (camizestrant) tablets — an oral estrogen receptor antagonist — in combination with…
This is for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer who are…
Lifyorli (relacorilant) — oral GR antagonist with nab-paclitaxel for platinum-resistant ovarian cancer
FDA traditional (full) approval on 25 March 2026 for Lifyorli (relacorilant) capsules — an oral glucocorticoid receptor (GR) antagonist — in…
This is for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer…
Beqalzi (sonrotoclax) — oral BCL-2 inhibitor for R/R mantle cell lymphoma after ≥2 lines including a BTK inhibitor
FDA accelerated approval on 13 May 2026 for Beqalzi (sonrotoclax) tablets — an oral BCL-2 inhibitor — for adults with relapsed or refractory…
This is for adults with relapsed or refractory mantle cell lymphoma who have already had at least two…
Zenbexus (iberdomide) — first labelled CELMoD for adults with multiple myeloma after ≥1 prior line
FDA accelerated approval on 13 August 2026 for Zenbexus (iberdomide) capsules — an oral cereblon-modulating protein degrader (CELMoD) — in…
This is for adults with multiple myeloma who have already had at least one prior treatment that included a…
Jideytro (zidesamtinib) — oral ROS1 kinase inhibitor after a prior ROS1 TKI
On 22 July 2026 the FDA labelled Jideytro (zidesamtinib) tablets for adults with locally advanced or metastatic ROS1-positive NSCLC who…
Jideytro is a US-labelled oral pill for adults whose ROS1-positive lung cancer has already been treated with…
Xocova / Zokovea (ensitrelvir) — oral COVID-19 post-exposure prophylaxis
The first FDA-labelled oral option for COVID-19 post-exposure prophylaxis (PEP). On 29 May 2026 the FDA approved Xocova (ensitrelvir) tablets…
The first FDA-labelled oral option for COVID-19 post-exposure prophylaxis (PEP). On 29 May 2026…
Utebzi (tebipenem pivoxil) — first oral carbapenem for adults with complicated UTI
The first FDA-approved oral carbapenem for adults. On 17 June 2026 the FDA labelled Utebzi (tebipenem pivoxil) tablets for complicated urinary…
The first FDA-approved oral carbapenem for adults. On 17 June 2026 the FDA labelled Utebzi…
Veppanu (vepdegestrant) — first FDA-approved PROTAC for ESR1-mutated ER+/HER2− advanced breast cancer
The FDA labelled a once-daily 200 mg oral PROTAC estrogen-receptor degrader tablet — take with food, swallow whole — for adults with ER-positive,…
The FDA labelled a once-daily 200 mg oral PROTAC estrogen-receptor degrader tablet — take with food,…
Baxfendy (baxdrostat) — first aldosterone-synthase inhibitor for adults whose blood pressure is not adequately controlled
The FDA labelled a once-daily 1 mg or 2 mg oral aldosterone synthase inhibitor tablet — take with or without food, swallow whole — in combination with…
The FDA labelled a once-daily 1 mg or 2 mg oral aldosterone synthase inhibitor tablet — take with or…
Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis — 12 and older, at least 40 kg
The FDA labelled a once-daily 200 mg oral IL-23 receptor peptide for moderate-to-severe plaque psoriasis in people 12 and older who weigh at least 40 kg and…
The FDA labelled a once-daily 200 mg oral IL-23 receptor peptide for moderate-to-severe plaque psoriasis in…
Rhapsido (remibrutinib) for adult chronic spontaneous urticaria still active on H1 antihistamines
The FDA, Health Canada, the European Commission, and the UK MHRA have labelled an oral BTK inhibitor — 25 mg twice daily — for adults with chronic spontaneous…
The FDA, Health Canada, the European Commission, and the UK MHRA have labelled an oral BTK inhibitor — 25 mg…
Lipfendra (enlicitide) — first oral PCSK9 inhibitor for high LDL-C in adults
The FDA labelled a once-daily 20 mg oral PCSK9 inhibitor tablet — take in the morning on an empty stomach — as an adjunct to diet and exercise to lower…
The FDA labelled a once-daily 20 mg oral PCSK9 inhibitor tablet — take in the morning on an empty…
Orzeyful (oveporexton) for narcolepsy type 1
The FDA labelled oveporexton for adults with narcolepsy type 1 on 5 August 2026 — and said it will be lawful to market only after DEA scheduling. Japan’s PMDA…
The FDA labelled oveporexton for adults with narcolepsy type 1 on 5 August 2026 — and said it will be lawful…
Foundayo (orforglipron) for chronic weight management
FDA labelled oral orforglipron for chronic weight management in adults. UK MHRA also labelled weight management and type 2 diabetes — those lines stay…
FDA labelled oral orforglipron for chronic weight management in adults. UK MHRA also labelled weight…
Lisraya (brepocitinib) — first oral TYK2/JAK1 tablet labelled for adult dermatomyositis
FDA labelled a once-daily 30 mg pill for dermatomyositis in adults (27 August 2026), with a boxed JAK-class…
Lynavoy (linerixibat) for cholestatic itch in adults with primary biliary cholangitis — oral IBAT inhibitor
The FDA (17 Mar 2026) and UK MHRA (1 May 2026) labelled an oral 40 mg tablet twice daily for cholestatic pruritus associated with primary biliary…
The FDA (17 Mar 2026) and UK MHRA (1 May 2026) labelled an oral 40 mg tablet twice daily for cholestatic…
Hyrnuo (sevabertinib) for HER2 TKD-mutant NSCLC
The FDA and Health Canada have labelled an oral HER2 tyrosine-kinase inhibitor for adults with locally advanced or metastatic NSCLC whose tumours have HER2…
The FDA and Health Canada have labelled an oral HER2 tyrosine-kinase inhibitor for adults with locally…
Rasonque (daraxonrasib): the first RAS(ON) pill for metastatic pancreatic adenocarcinoma
The FDA approved this RAS(ON) pill on 26 August 2026 for metastatic pancreatic adenocarcinoma. It is not a Canadian pharmacy drug. SAP, a first-line trial…
The FDA approved this RAS(ON) pill on 26 August 2026 for metastatic pancreatic adenocarcinoma. It is not a…
Jascayd (nerandomilast) for IPF and PPF
The FDA, Europe, and the UK have labelled nerandomilast for adults with idiopathic pulmonary fibrosis and for adults with progressive pulmonary fibrosis.…
The FDA, Europe, and the UK have labelled nerandomilast for adults with idiopathic pulmonary fibrosis and for…
Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy
The FDA, Europe, the UK, and China have labelled aficamten for symptomatic obstructive HCM in adults. England's NHS has a 30-day funding clock from NICE.…
The FDA, Europe, the UK, and China have labelled aficamten for symptomatic obstructive HCM in adults.…